bioRxiv Science⌕ Search

Biology subjects

Endoh, H.

Publications and source records attributed to Endoh, H..

2 recordsLinked to original sources

BRM preserves sinusoidal niche integrity to prevent microenvironmental senescence and sustain hematopoietic stem cells

During aging and stress, remodeling of the bone marrow (BM) microenvironment compromises hematopoietic stem cell (HSC) maintenance, contributing to an extrinsic HSC aging phenotype. Although niche-derived Notch signaling is essential for hematopoietic regeneration following myelosuppressive injury, the upstream epigenetic mechanisms that regulate this stress-responsive signaling remain poorly understood. Here, we identify the chromatin remodeler BRM (SMARCA2) as a critical regulator of the BM sinusoidal niche that preserves vascular integrity and hematopoietic regeneration. Using reciprocal BM transplantation, we demonstrate that a Brm-deficient microenvironment impairs HSC repopulating capacity and imposes an aging-like myeloid bias characterized by expansion of granulocyte-monocyte progenitors. Following 5-fluorouracil (5-FU)-induced myelosuppression, BrmKO mice exhibit defective sinusoidal regeneration accompanied by endothelial degeneration. Mechanistically, BRM deficiency attenuates endothelial Notch signaling by impairing stress-induced Notch2 expression in sinusoidal endothelial cells (SECs), while simultaneously reducing Jag2 ligand pool through persistent depletion of SECs and impaired stress-induced expansion of Jag2-producing LepR-positive stromal cells. These alterations attenuate endothelial Notch signaling, resulting in defective sinusoidal regeneration, loss of mesenchymal niche support, and progressive displacement of HSCs from the sinusoidal vasculature. Notably, Brm expression is physiologically reduced in aged wild-type SECs and LepR-positive stromal cells. Collectively, our findings identify BRM as a key epigenetic regulator of bone marrow niche integrity and suggest that age-associated BRM decline contributes to niche dysfunction and hematopoietic aging. Key PointsO_LIBRM preserves the bone marrow niche to sustain HSC repopulating capacity and prevent aging-associated myeloid bias. C_LIO_LIBRM preserves stress-responsive Notch signaling in the bone marrow niche, thereby maintaining sinusoidal integrity and HSC localization. C_LI

immunology↗

Highly selective SGLT2 inhibitors suppress glucose uptake in alpha-TC1 cells, while glucagon secretion is not affected.

The existence of sodium-glucose cotransporter 2 (SGLT2) in pancreatic alpha cells and its potential roles in glucagon secretion remain controversial, despite its well-established function in renal glucose reabsorption. While some studies suggest SGLT2 presence and its involvement in glucagon regulation, others deny its expression in alpha cells. To clarify this dispute, we investigated the functional effects of highly selective SGLT2 inhibitors, dapagliflozin and empagliflozin, on glucose uptake, intracellular ATP levels, and glucagon secretion in alpha-TC1 cells, a widely used model for glucagon-secreting cells in culture. The SGLT2 inhibitors significantly suppressed basal glucose uptake in alpha-TC1 cells, indicating functional SGLT2 presence. However, the inhibitors did not affect glucagon secretion. Neither the SGLT2 inhibitors nor the more potent glucose transport inhibitor, cytochalasin B, altered intracellular ATP levels or glucagon secretion. In contrast, pharmacological inhibition of K/ATP channels increased glucagon secretion without affecting glucose uptake or ATP levels. These results suggest that while SGLT2 is functionally present at low levels and mediates basal glucose uptake in alpha-TC1 cells, its inhibition has insufficient influence on intracellular ATP levels, and therefore glucagon secretion remains stable. Furthermore, our observations support predominant involvement of K/ATP channels in regulating glucagon secretion. Further studies in human purified pancreatic alpha cells in addition to islets are warranted to fully elucidate SGLT2s role in alpha-cell physiology.

pharmacology and toxicology↗